Skip to main content

Advertisement

SpringerLink
Log in

Autoimmunity in 2019

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Based on the PubMed data, we have been performing a yearly evaluation of the publications related to autoimmune diseases and immunology to ascertain the relative weight of the former in the scientific literature. It is particularly intriguing to observe that despite the numerous new avenues of immune-related mechanisms, such as cancer immunotherapy, the proportion of immunology manuscripts related to autoimmunity continues to increase and has been approaching 20% in 2019. As in the previous 13 years, we performed an arbitrary selection of the peer-reviewed articles published by the major dedicated Journals and discussed the common themes which continue to outnumber peculiarites in autoimmune diseases. The investigated areas included systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), psoriatic arthritis (PsA), autoantibodies (autoAbs), and common therapeutic avenues and novel pathogenic mechanisms for autoimmune conditions. Some examples include new pathogenetic evidence which is well represented by IL21 or P2X7 receptor (P2X7R) in SLE or the application of single-cell RNA sequencing (scRNA-seq), mass cytometry, bulk RNA sequencing (RNA-seq), and flow cytometry for the analysis of different cellular populations in RA. Cumulatively and of interest to the clinicians, a large number of findings continue to underline the importance of a strict relationship between basic and clinical science to define new pathogenetic and therapeutic developments. The therapeutic pipeline in autoimmunity continues to grow and maintain a constant flow of new molecules, as well illustrated in RA and PsA, and this is most certainly derived from the new basic evidence and the high-throughput tools applied to autoimmune diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Zanatta E, Famoso G, Boscain F, Montisci R, Pigatto E, Polito P et al (2019) Nailfold avascular score and coronary microvascular dysfunction in systemic sclerosis: a newsworthy association. Autoimmun Rev 18:177–183

    Article  PubMed  Google Scholar 

  2. Yao Q, Song Z, Wang B, Zhang JA, Mu K (2019) Thyroid disorders in patients with systemic sclerosis: a systematic review and meta-analysis. Autoimmun Rev 18:634–636

    Article  PubMed  Google Scholar 

  3. Suto T, Karonitsch T (2020) The immunobiology of mTOR in autoimmunity. J Autoimmun 110:102373

    Article  CAS  PubMed  Google Scholar 

  4. Smith V, Vanhaecke A, Herrick AL, Distler O, Guerra MG, Denton CP et al (2019) Fast track algorithm: how to differentiate a "scleroderma pattern" from a "non-scleroderma pattern". Autoimmun Rev 18:102394

    Article  PubMed  Google Scholar 

  5. Sciascia S, Cecchi I, Massara C, Rossi D, Radin M, Ladehesa PL et al (2020) Thermography in systemic sclerosis patients and other rheumatic diseases: diagnosis, disease activity assessment, and therapeutic monitoring. Autoimmun Rev 19:102449

    Article  PubMed  Google Scholar 

  6. Riccardi A, Marcoccia A, Borgia A, Guastafierro T, Bondanini F, Fasano S et al (2019) Undifferentiated connective tissue disease at risk of systemic sclerosis: a weighted score to identify patients who will evolve. Autoimmun Rev 18:102358

    Article  PubMed  Google Scholar 

  7. Narvaez J, Pirola JP, LLuch J, Juarez P, Nolla JM, Valenzuela A (2019) Effectiveness and safety of rituximab for the treatment of refractory systemic sclerosis associated calcinosis: a case series and systematic review of the literature. Autoimmun Rev 18:262–269

    Article  CAS  PubMed  Google Scholar 

  8. Napodano C, Pocino K, Rigante D, Stefanile A, Gulli F, Marino M et al (2019) Free light chains and autoimmunity. Autoimmun Rev 18:484–492

    Article  CAS  PubMed  Google Scholar 

  9. Molano-Gonzalez N, Rojas M, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Rodriguez Y et al (2019) Cluster analysis of autoimmune rheumatic diseases based on autoantibodies. New insights for polyautoimmunity. J Autoimmun 98:24–32

    Article  CAS  PubMed  Google Scholar 

  10. Meridor K, Levy Y (2020) Systemic sclerosis induced by CNS stimulants for ADHD: a case series and review of the literature. Autoimmun Rev 19:102439

    Article  CAS  PubMed  Google Scholar 

  11. Marie I (2019) Systemic sclerosis and exposure to heavy metals. Autoimmun Rev 18:62–72

    Article  CAS  PubMed  Google Scholar 

  12. Jafarinejad-Farsangi S, Gharibdoost F, Farazmand A, Kavosi H, Jamshidi A, Karimizadeh E et al (2019) MicroRNA-21 and microRNA-29a modulate the expression of collagen in dermal fibroblasts of patients with systemic sclerosis. Autoimmunity 52:108–116

    Article  PubMed  Google Scholar 

  13. Henry TW, Mendoza FA, Jimenez SA (2019) Role of microRNA in the pathogenesis of systemic sclerosis tissue fibrosis and vasculopathy. Autoimmun Rev 18:102396

    Article  CAS  PubMed  Google Scholar 

  14. Frantz C, Huscher D, Avouac J, Hachulla E, Balbir-Gurman A, Riemekasten G et al (2020) Outcomes of limited cutaneous systemic sclerosis patients: results on more than 12,000 patients from the EUSTAR database. Autoimmun Rev 19:102452

    Article  PubMed  Google Scholar 

  15. Chaigne B, Rodeia S, Benmostefa N, Berezne A, Authier J, Cohen P et al (2020) Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: a comparative study in 52 patients. Autoimmun Rev 19:102431

    Article  PubMed  CAS  Google Scholar 

  16. Cattalini M, Soliani M, Caparello MC, Cimaz R (2019) Sex differences in pediatric rheumatology. Clin Rev Allergy Immunol 56:293–307

    Article  CAS  PubMed  Google Scholar 

  17. Blagojevic J, Legendre P, Matucci-Cerinic M, Mouthon L (2019) Is there today a place for corticosteroids in the treatment of scleroderma? Autoimmun Rev 18:102403

    Article  PubMed  CAS  Google Scholar 

  18. Bellan M, Patrucco F, Barone-Adesi F, Gavelli F, Castello LM, Nerviani A et al (2020) Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: a systematic review. Autoimmun Rev 19:102453

    Article  CAS  PubMed  Google Scholar 

  19. Barrat FJ, Crow MK, Ivashkiv LB (2019) Interferon target-gene expression and epigenomic signatures in health and disease. Nat Immunol 20:1574–1583

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Lescoat A, Ballerie A, Jouneau S, Fardel O, Vernhet L, Jego P et al (2019) M1/M2 polarisation state of M-CSF blood-derived macrophages in systemic sclerosis. Ann Rheum Dis 78:e127

    Article  PubMed  CAS  Google Scholar 

  21. Skaug B, Khanna D, Swindell WR, Hinchcliff ME, Frech TM, Steen VD et al (2020) Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Ann Rheum Dis 79:379–386

    Article  CAS  PubMed  Google Scholar 

  22. Skarstein K, Jensen JL, Galtung H, Jonsson R, Brokstad K, Aqrawi LA (2019) Autoantigen-specific B cells and plasma cells are prominent in areas of fatty infiltration in salivary glands of patients with primary Sjogren's syndrome. Autoimmunity 52:242–250

    Article  CAS  PubMed  Google Scholar 

  23. Shin JI, Lee KH, Joo YH, Lee JM, Jeon J, Jung HJ et al (2019) Inflammasomes and autoimmune and rheumatic diseases: a comprehensive review. J Autoimmun 103:102299

    Article  CAS  PubMed  Google Scholar 

  24. Martin-Nares E, Hernandez-Molina G (2019) Novel autoantibodies in Sjogren's syndrome: a comprehensive review. Autoimmun Rev 18:192–198

    Article  CAS  PubMed  Google Scholar 

  25. Malagon C, Gomez MDP, Mosquera C, Vargas C, Gonzalez T, Arango C et al (2019) Juvenile polyautoimmunity in a rheumatology setting. Autoimmun Rev 18:369–381

    Article  PubMed  Google Scholar 

  26. Long D, Chen Y, Wu H, Zhao M, Lu Q (2019) Clinical significance and immunobiology of IL-21 in autoimmunity. J Autoimmun 99:1–14

    Article  CAS  PubMed  Google Scholar 

  27. Huang C, Zhu HX, Yao Y, Bian ZH, Zheng YJ, Li L et al (2019) Immune checkpoint molecules Possible future therapeutic implications in autoimmune diseases. J Autoimmun 104:102333

    Article  CAS  PubMed  Google Scholar 

  28. Ferrari SM, Fallahi P, Ruffilli I, Elia G, Ragusa F, Benvenga S et al (2019) The association of other autoimmune diseases in patients with Graves' disease (with or without ophthalmopathy): review of the literature and report of a large series. Autoimmun Rev 18:287–292

    Article  PubMed  Google Scholar 

  29. Clancy RM, Marion MC, Ainsworth HC, Blaser MJ, Chang M, Howard TD et al (2020) Salivary dysbiosis and the clinical spectrum in anti-Ro positive mothers of children with neonatal lupus. J Autoimmun 107:102354

    Article  CAS  PubMed  Google Scholar 

  30. Clancy RM, Halushka M, Rasmussen SE, Lhakhang T, Chang M, Buyon JP (2019) Siglec-1 macrophages and the contribution of IFN to the development of autoimmune congenital heart block. J Immunol 202:48–55

    Article  CAS  PubMed  Google Scholar 

  31. Applbaum E, Lichtbroun A (2019) Novel Sjogren's autoantibodies found in fibromyalgia patients with sicca and/or xerostomia. Autoimmun Rev 18:199–202

    Article  CAS  PubMed  Google Scholar 

  32. Anaya JM, Restrepo-Jimenez P, Rodriguez Y, Rodriguez-Jimenez M, Acosta-Ampudia Y, Monsalve DM et al (2019) Sjogren's syndrome and autoimmune thyroid disease: two sides of the same coin. Clin Rev Allergy Immunol 56:362–374

    Article  PubMed  Google Scholar 

  33. Dorner T, Posch MG, Li Y, Petricoul O, Cabanski M, Milojevic JM et al (2019) Treatment of primary Sjogren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Ann Rheum Dis 78:641–647

    Article  PubMed  CAS  Google Scholar 

  34. Ramos-Casals M, Brito-Zeron P, Bombardieri S, Bootsma H, De Vita S, Dorner T et al (2020) EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies. Ann Rheum Dis 79:3–18

    Article  CAS  PubMed  Google Scholar 

  35. van der Meulen TA, van Nimwegen JF, Harmsen HJM, Liefers SC, van der Tuuk K, Kroese FGM et al (2019) Normal vaginal microbiome in women with primary Sjogren's syndrome-associated vaginal dryness. Ann Rheum Dis 78:707–709

    Article  PubMed  CAS  Google Scholar 

  36. Lee J, Baek S, Koh JH, Kim JW, Kim SY, Chung SH et al (2019) Soluble siglec-5 is a novel salivary biomarker for primary Sjogren's syndrome. J Autoimmun 100:114–119

    Article  CAS  PubMed  Google Scholar 

  37. Wu X, Liu Y, Wei W, Liu ML (2019) Extracellular vesicles in autoimmune vasculitis - little dirts light the fire in blood vessels. Autoimmun Rev 18:593–606

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Watanabe-Kusunoki K, Nakazawa D, Kusunoki Y, Kudo T, Hattanda F, Nishio S et al (2020) Recombinant thrombomodulin ameliorates autoimmune vasculitis via immune response regulation and tissue injury protection. J Autoimmun 108:102390

    Article  CAS  PubMed  Google Scholar 

  39. Wang C, Deng H, Gong Y, You R, Chen M, Zhao MH (2020) Effect of high mobility group box 1 on toll-like receptor 9 in B cells in myeloperoxidase-ANCA-associated vasculitis. Autoimmunity 53:28–34

    Article  CAS  PubMed  Google Scholar 

  40. Walls CA, Basu N, Hutcheon G, Erwig LP, Little MA, Kidder D (2020) A novel 4-dimensional live-cell imaging system to study leukocyte-endothelial dynamics in ANCA-associated vasculitis. Autoimmunity 53:148–155

    Article  PubMed  Google Scholar 

  41. Tahvildari M, Dana R (2019) Low-dose IL-2 therapy in transplantation, autoimmunity, and inflammatory diseases. J Immunol 203:2749–2755

    Article  CAS  PubMed  Google Scholar 

  42. Hamano Y, Ito F, Suzuki O, Koura M, Matsuoka S, Kobayashi T et al (2019) Vasculitis and crescentic glomerulonephritis in a newly established congenic mouse strain derived from ANCA-associated vasculitis-prone SCG/Kj mice. Autoimmunity 52:208–219

    Article  CAS  PubMed  Google Scholar 

  43. Frangou E, Vassilopoulos D, Boletis J, Boumpas DT (2019) An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): implications for the pathogenesis and treatment. Autoimmun Rev 18:751–760

    Article  CAS  PubMed  Google Scholar 

  44. Enocsson H, Wirestam L, Dahle C, Padyukov L, Jonsen A, Urowitz MB et al (2020) Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. J Autoimmun 106:102340

    Article  CAS  PubMed  Google Scholar 

  45. Dolff S, Witzke O, Wilde B (2019) Th17 cells in renal inflammation and autoimmunity. Autoimmun Rev 18:129–136

    Article  CAS  PubMed  Google Scholar 

  46. Klapa S, Muller A, Koch A, Heidecke H, Kahler W, Junker J et al (2019) Decreased endothelin receptor A autoantibody levels are associated with early ischaemic events in patients with giant-cell arteritis. Ann Rheum Dis 78:1443–1444

    Article  CAS  PubMed  Google Scholar 

  47. Kong X, Sawalha AH (2019) Takayasu arteritis risk locus in IL6 represses the anti-inflammatory gene GPNMB through chromatin looping and recruiting MEF2-HDAC complex. Ann Rheum Dis 78:1388–1397

    Article  CAS  PubMed  Google Scholar 

  48. Michailidou D, Rosenblum JS, Rimland CA, Marko J, Ahlman MA, Grayson PC (2020) Clinical symptoms and associated vascular imaging findings in Takayasu's arteritis compared to giant cell arteritis. Ann Rheum Dis 79:262–267

    Article  CAS  PubMed  Google Scholar 

  49. Vandergheynst FA, Lelubre C (2019) Mycophenolate mofetil: a step forward in the induction treatment of ANCA-associated vasculitis? Comment on the article by Jones et al. Annals of the rheumatic diseases

  50. Dieudonne Y, Gies V, Guffroy A, Keime C, Bird AK, Liesveld J et al (2019) Transitional B cells in quiescent SLE: an early checkpoint imprinted by IFN. J Autoimmun 102:150–158

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Pisetsky DS (2020) Evolving story of autoantibodies in systemic lupus erythematosus. J Autoimmun 110:102356

    Article  CAS  PubMed  Google Scholar 

  52. Franks SE, Getahun A, Cambier JC (2019) A precision B cell-targeted therapeutic approach to autoimmunity caused by phosphatidylinositol 3-kinase pathway dysregulation. J Immunol 202:3381–3393

    Article  CAS  PubMed  Google Scholar 

  53. Feng Y, Yang M, Wu H, Lu Q (2020) The pathological role of B cells in systemic lupus erythematosus: from basic research to clinical. Autoimmunity 53:56–64

    Article  CAS  PubMed  Google Scholar 

  54. Cao F, Hu LQ, Yao SR, Hu Y, Wang DG, Fan YG et al (2019) P2X7 receptor: a potential therapeutic target for autoimmune diseases. Autoimmun Rev 18:767–777

    Article  CAS  PubMed  Google Scholar 

  55. Pernis AB, Ivashkiv LB (2019) ‘-Omics’ shed light on B cells in lupus. Nat Immunol 20:946–948

    Article  CAS  PubMed  Google Scholar 

  56. Cunningham MA, Richard ML, Wirth JR, Scott JL, Eudaly J, Ruiz P et al (2019) Novel mechanism for estrogen receptor alpha modulation of murine lupus. J Autoimmun 97:59–69

    Article  CAS  PubMed  Google Scholar 

  57. Syrett CM, Sierra I, Beethem ZT, Dubin AH, Anguera MC (2020) Loss of epigenetic modifications on the inactive X chromosome and sex-biased gene expression profiles in B cells from NZB/W F1 mice with lupus-like disease. J Autoimmun 107:102357

    Article  CAS  PubMed  Google Scholar 

  58. Lownik JC, Wimberly JL, Conrad DH, Martin RK (2019) B cell ADAM10 controls murine lupus progression through regulation of the ICOS:ICOS ligand axis. J Immunol 202:664–674

    Article  CAS  PubMed  Google Scholar 

  59. Giltiay NV, Giordano D, Clark EA (2019) The plasticity of newly formed B cells. J Immunol 203:3095–3104

    Article  CAS  PubMed  Google Scholar 

  60. Liu X, Zhang W, Zhao M, Fu L, Liu L, Wu J et al (2019) T cell receptor beta repertoires as novel diagnostic markers for systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 78:1070–1078

    Article  CAS  PubMed  Google Scholar 

  61. Frangou E, Chrysanthopoulou A, Mitsios A, Kambas K, Arelaki S, Angelidou I et al (2019) REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A). Ann Rheum Dis 78:238–248

    Article  CAS  PubMed  Google Scholar 

  62. Linge P, Arve S, Olsson LM, Leonard D, Sjowall C, Frodlund M et al (2020) NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus. Ann Rheum Dis 79:254–261

    Article  CAS  PubMed  Google Scholar 

  63. Odqvist L, Jevnikar Z, Riise R, Oberg L, Rhedin M, Leonard D et al (2019) Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus. Ann Rheum Dis 78:1363–1370

    Article  CAS  PubMed  Google Scholar 

  64. Bach M, Moon J, Moore R, Pan T, Nelson JL, Lood C (2020) A neutrophil activation biomarker panel in prognosis and monitoring of patients with rheumatoid arthritis. Arthritis Rheum 72:47–56

    Article  CAS  Google Scholar 

  65. Curran CS, Gupta S, Sanz I, Sharon E (2019) PD-1 immunobiology in systemic lupus erythematosus. J Autoimmun 97:1–9

    Article  CAS  PubMed  Google Scholar 

  66. Horuluoglu B, Bayik D, Kayraklioglu N, Goguet E, Kaplan MJ, Klinman DM (2019) PAM3 supports the generation of M2-like macrophages from lupus patient monocytes and improves disease outcome in murine lupus. J Autoimmun 99:24–32

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Panousis NI, Bertsias GK, Ongen H, Gergianaki I, Tektonidou MG, Trachana M et al (2019) Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. Ann Rheum Dis 78:1079–1089

    Article  CAS  PubMed  Google Scholar 

  68. Wang B, Chen S, Zheng Q, Gao Z, Chen R, Xuan J et al. (2019) Development and initial validation of diagnostic gene signatures for systemic lupus erythematosus. Ann Rheum Dis

  69. Wang Y, Chen S, Chen J, Xie X, Gao S, Zhang C et al (2020) Germline genetic patterns underlying familial rheumatoid arthritis, systemic lupus erythematosus and primary Sjogren's syndrome highlight T cell-initiated autoimmunity. Ann Rheum Dis 79:268–275

    Article  CAS  PubMed  Google Scholar 

  70. Zhang SX, Wang J, Chen JW, Zhang MX, Zhang YF, Hu FY et al. (2019) The level of peripheral regulatory T cells is linked to changes in gut commensal microflora in patients with systemic lupus erythematosus Ann Rheum Dis

  71. Zhao Z, Ren J, Dai C, Kannapell CC, Wang H, Gaskin F et al (2019) Nature of T cell epitopes in lupus antigens and HLA-DR determines autoantibody initiation and diversification. Ann Rheum Dis 78:380–390

    Article  CAS  PubMed  Google Scholar 

  72. Anaya-Macias BU, De la Cruz-Mosso U, Palafox-Sanchez CA, Parra-Rojas I, Martinez-Bonilla G, Gonzalez-Lopez L et al (2020) The -675 4G/5G PAI-1 polymorphism confers genetic susceptibility to systemic lupus erythematosus, its clinical manifestations, and comorbidities in Mexican-Mestizo population. Autoimmunity 53:71–77

    Article  CAS  PubMed  Google Scholar 

  73. Liu LN, Wang P, Zou YF, Xu Z, Cheng J, Zhang Y et al (2019) Semaphorin-3A, semaphorin-7A gene single nucleotide polymorphisms, and systemic lupus erythematosus susceptibility. Autoimmunity 52:161–167

    Article  CAS  PubMed  Google Scholar 

  74. Murdaca G, Tonacci A, Negrini S, Greco M, Borro M, Puppo F et al (2019) Emerging role of vitamin D in autoimmune diseases: an update on evidence and therapeutic implications. Autoimmun Rev 18:102350

    Article  CAS  PubMed  Google Scholar 

  75. Correa Freitas E, Evelyn Karnopp T, de Souza Silva JM, Cavalheiro do Espirito Santo R, da Rosa TH, de Oliveira MS et al (2019) Vitamin D supplementation ameliorates arthritis but does not alleviates renal injury in pristane-induced lupus model. Autoimmunity 52:69–77

    Article  PubMed  CAS  Google Scholar 

  76. Soni C, Sinha I, Fasnacht MJ, Olsen NJ, Rahman ZSM, Sinha R (2019) Selenium supplementation suppresses immunological and serological features of lupus in B6.Sle1b mice. Autoimmunity 52:57–68

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Briand C, Fremond ML, Bessis D, Carbasse A, Rice GI, Bondet V et al (2019) Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency. Ann Rheum Dis 78:431–433

    Article  PubMed  Google Scholar 

  78. Goropevsek A, Holcar M, Pahor A, Avcin T (2019) STAT signaling as a marker of SLE disease severity and implications for clinical therapy. Autoimmun Rev 18:144–154

    Article  CAS  PubMed  Google Scholar 

  79. Dall'Era M, Pauli ML, Remedios K, Taravati K, Sandova PM, Putnam AL et al (2019) Adoptive Treg cell therapy in a patient with systemic lupus erythematosus. Arthritis Rheum 71:431–440

    Article  CAS  Google Scholar 

  80. Zhang F, Wei K, Slowikowski K, Fonseka CY, Rao DA, Kelly S et al (2019) Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat Immunol 20:928–942

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  81. Scheinecker C, Goschl L, Bonelli M (2020) Treg cells in health and autoimmune diseases: new insights from single cell analysis. J Autoimmun 110:102376

    Article  CAS  PubMed  Google Scholar 

  82. Cammarata I, Martire C, Citro A, Raimondo D, Fruci D, Melaiu O et al (2019) Counter-regulation of regulatory T cells by autoreactive CD8(+) T cells in rheumatoid arthritis. J Autoimmun 99:81–97

    Article  CAS  PubMed  Google Scholar 

  83. Ribon M, Seninet S, Mussard J, Sebbag M, Clavel C, Serre G et al (2019) Neutrophil extracellular traps exert both pro- and anti-inflammatory actions in rheumatoid arthritis that are modulated by C1q and LL-37. J Autoimmun 98:122–131

    Article  CAS  PubMed  Google Scholar 

  84. El Shikh MEM, El Sayed R, Nerviani A, Goldmann K, John CR, Hands R et al (2019) Extracellular traps and PAD4 released by macrophages induce citrullination and auto-antibody production in autoimmune arthritis. J Autoimmun 105:102297

    Article  PubMed  CAS  Google Scholar 

  85. Peene I, Elewaut D (2019) Changing the wolf from outside: how microbiota trigger systemic lupus erythematosus. Ann Rheum Dis 78:867–869

    Article  PubMed  Google Scholar 

  86. Silverman GJ, Azzouz DF (2019) Response to: 'The level of peripheral regulatory T cells is linked to changes in gut commensal microflora in patients with systemic lupus erythematosus' by Zhang et al and the phylogeny of a candidate pathobiont in lupus nephritis. Ann Rheum Dis

  87. van Dijkhuizen EHP, Del Chierico F, Malattia C, Russo A, Pires Marafon D, Ter Haar NM et al (2019) Microbiome analytics of the gut microbiota in patients with juvenile idiopathic arthritis: a longitudinal observational cohort study. Arthritis Rheum 71:1000–1010

    Article  CAS  Google Scholar 

  88. Asquith M, Sternes PR, Costello ME, Karstens L, Diamond S, Martin TM et al (2019) HLA alleles associated with risk of ankylosing spondylitis and rheumatoid arthritis influence the gut microbiome. Arthritis Rheum 71:1642–1650

    Article  CAS  Google Scholar 

  89. Zhou C, Zhao H, Xiao XY, Chen BD, Guo RJ, Wang Q et al (2020) Metagenomic profiling of the pro-inflammatory gut microbiota in ankylosing spondylitis. J Autoimmun 107:102360

    Article  CAS  PubMed  Google Scholar 

  90. Wells PM, Williams FMK, Matey-Hernandez ML, Menni C, Steves CJ (2019) RA and the microbiome: Do host genetic factors provide the link? J Autoimmun 99:104–115

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Zhao CN, Xu Z, Wu GC, Mao YM, Liu LN, Qian W et al (2019) Emerging role of air pollution in autoimmune diseases. Autoimmun Rev 18:607–614

    Article  CAS  PubMed  Google Scholar 

  92. Yang XK, Liu J, Chen SY, Li M, Zhang MM, Leng RX et al (2019) UBASH3A gene polymorphisms and expression profile in rheumatoid arthritis. Autoimmunity 52:21–26

    Article  CAS  PubMed  Google Scholar 

  93. Regueiro C, Rodriguez-Rodriguez L, Triguero-Martinez A, Nuno L, Castano-Nunez AL, Villalva A et al (2019) Specific association of HLA-DRB1*03 with anti-carbamylated protein antibodies in patients with rheumatoid arthritis. Arthritis Rheum 71:331–339

    Article  CAS  Google Scholar 

  94. Plant D, Maciejewski M, Smith S, Nair N, Hyrich K, Ziemek D et al (2019) Profiling of gene expression biomarkers as a classifier of methotrexate nonresponse in patients with rheumatoid arthritis. Arthritis Rheum 71:678–684

    Article  CAS  Google Scholar 

  95. Shen F, Verma AH, Volk A, Jones B, Coleman BM, Loza MJ et al (2019) Combined blockade of TNF-alpha and IL-17A alleviates progression of collagen-induced arthritis without causing serious infections in mice. J Immunol 202:2017–2026

    Article  CAS  PubMed  Google Scholar 

  96. Lorenzetti R, Janowska I, Smulski CR, Frede N, Henneberger N, Walter L et al (2019) Abatacept modulates CD80 and CD86 expression and memory formation in human B-cells. J Autoimmun 101:145–152

    Article  CAS  PubMed  Google Scholar 

  97. De Santis M, Isailovic N, Generali E, Ceribelli A, Altamore L, Real-Fernandez F et al (2019) Humoral response against LL-37 in psoriatic disease: comment on the article by Yuan et al. Arthritis Rheum 71:1964–1965

    Article  Google Scholar 

  98. Yuan Y, Qiu J, Lin ZT, Li W, Haley C, Mui UN et al (2019) Identification of novel autoantibodies associated with psoriatic arthritis. Arthritis Rheum 71:941–951

    Article  CAS  Google Scholar 

  99. Sobchak C, Akhtari S, Harvey P, Gladman D, Chandran V, Cook R et al (2019) Value of carotid ultrasound in cardiovascular risk stratification in patients with psoriatic disease. Arthritis Rheum 71:1651–1659

    Article  Google Scholar 

  100. Savage L, Goodfield M, Horton L, Watad A, Hensor E, Emery P et al (2019) Regression of peripheral subclinical enthesopathy in therapy-naive patients treated with ustekinumab for moderate-to-severe chronic plaque psoriasis: a fifty-two-week, prospective, open-label feasibility study. Arthritis Rheum 71:626–631

    Article  CAS  Google Scholar 

  101. Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A et al (2019) Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheum 71:5–32

    Article  Google Scholar 

  102. Chattopadhyay A, Sharma SK, Naidu S, Dhir V (2019) Failure of etanercept and methotrexate combination therapy to surpass etanercept monotherapy in psoriatic arthritis-What about the joint counts? Comment on the Article by Mease et al. Arthritis Rheum 71:1965–1966

    Article  Google Scholar 

  103. Siebert S, Sweet K, Dasgupta B, Campbell K, McInnes IB, Loza MJ (2019) Responsiveness of serum C-reactive protein, interleukin-17A, and interleukin-17F levels to ustekinumab in psoriatic arthritis: lessons from two phase III, multicenter, double-blind, placebo-controlled trials. Arthritis Rheum 71:1660–1669

    Article  CAS  Google Scholar 

  104. Merola JF, Ogdie A (2019) SEAM-PsA: seems like methotrexate works in psoriatic arthritis? Arthritis Rheum 71:1027–1029

    Article  Google Scholar 

  105. Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L et al (2019) Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheum 71:1112–1124

    Article  CAS  Google Scholar 

  106. Agrawal M, Shah S, Patel A, Pinotti R, Colombel JF, Burisch J (2019) Changing epidemiology of immune-mediated inflammatory diseases in immigrants: a systematic review of population-based studies. J Autoimmun 105:102303

    Article  PubMed  PubMed Central  Google Scholar 

  107. Bernink JH, Ohne Y, Teunissen MBM, Wang J, Wu J, Krabbendam L et al (2019) c-Kit-positive ILC2s exhibit an ILC3-like signature that may contribute to IL-17-mediated pathologies. Nat Immunol 20:992–1003

    Article  CAS  PubMed  Google Scholar 

  108. Chimenti MS, Caso F, Alivernini S, De Martino E, Costa L, Tolusso B et al (2019) Amplifying the concept of psoriatic arthritis: the role of autoimmunity in systemic psoriatic disease. Autoimmun Rev 18:565–575

    Article  CAS  PubMed  Google Scholar 

  109. Bergua C, Chiavelli H, Allenbach Y, Arouche-Delaperche L, Arnoult C, Bourdenet G et al (2019) In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Ann Rheum Dis 78:131–139

    Article  CAS  PubMed  Google Scholar 

  110. Betancur JF, Gomez-Puerta JA (2020) Antinuclear antibodies mitotic patterns and their clinical associations. Ann Rheum Dis 79:e63

    Article  PubMed  Google Scholar 

  111. Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ et al (2019) Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis 78:879–889

    Article  CAS  PubMed  Google Scholar 

  112. Deng C, Qu X, Cheng S, Zeng X, Li Y, Fei Y (2019) Decision-making value of nuclear dense fine speckled pattern in systemic autoimmune rheumatic disease: trick or treat? Ann Rheum Dis

  113. Greco M, Garcia de Yebenes MJ, Alarcon I, Brandy-Garcia AM, Rua-Figueroa I, Loza E et al (2020) Antisynthetase antibodies in clinical laboratories: the importance of clinical correlation and indirect immunofluorescence. Response to: Comment on: 'Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria' by Greco et al' by Knitza et al. Ann Rheum Dis 79:e87

    Article  PubMed  Google Scholar 

  114. Lee AYS, Beroukas D, Roberts-Thomson PJ (2020) Utility of the HEp-2000 antinuclear antibody substrate. Ann Rheum Dis 79:e67

    Article  PubMed  Google Scholar 

  115. Rothwell S, Chinoy H, Lamb JA, Miller FW, Rider LG, Wedderburn LR et al (2019) Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Ann Rheum Dis 78:996–1002

    Article  CAS  PubMed  Google Scholar 

  116. Sabbagh S, Pinal-Fernandez I, Kishi T, Targoff IN, Miller FW, Rider LG et al (2019) Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis 78:988–995

    Article  PubMed  CAS  Google Scholar 

  117. Spielmann L, Nespola B, Severac F, Andres E, Kessler R, Guffroy A et al (2019) Anti-Ku syndrome with elevated CK and anti-Ku syndrome with anti-dsDNA are two distinct entities with different outcomes. Ann Rheum Dis 78:1101–1106

    Article  CAS  PubMed  Google Scholar 

  118. van Delft MAM, van der Woude D, Toes REM, Trouw LA (2019) Secretory form of rheumatoid arthritis-associated autoantibodies in serum are mainly of the IgM isotype, suggesting a continuous reactivation of autoantibody responses at mucosal surfaces. Ann Rheum Dis 78:146–148

    Article  PubMed  CAS  Google Scholar 

  119. Vulsteke JB, Van Hoovels L, Willems P, Vander Cruyssen B, Vanderschueren S, Westhovens R et al. (2019) Titre-specific positive predictive value of antinuclear antibody patterns. Ann Rheum Dis

  120. Andrianova IA, Ponomareva AA, Mordakhanova ER, Le Minh G, Daminova AG, Nevzorova TA et al (2020) In systemic lupus erythematosus anti-dsDNA antibodies can promote thrombosis through direct platelet activation. J Autoimmun 107:102355

    Article  CAS  PubMed  Google Scholar 

  121. Germar K, Fehres CM, Scherer HU, van Uden N, Pollastro S, Yeremenko N et al (2019) Generation and characterization of anti-citrullinated protein antibody-producing B cell clones from rheumatoid arthritis patients. Arthritis Rheum 71:340–350

    Article  CAS  Google Scholar 

  122. Hoshino-Negishi K, Ohkuro M, Nakatani T, Kuboi Y, Nishimura M, Ida Y et al (2019) Role of anti-fractalkine antibody in suppression of joint destruction by inhibiting migration of osteoclast precursors to the synovium in experimental arthritis. Arthritis Rheum 71:222–231

    Article  CAS  Google Scholar 

  123. Kelmenson LB, Wagner BD, McNair BK, Frazer-Abel A, Demoruelle MK, Bergstedt DT et al (2020) Timing of elevations of autoantibody isotypes prior to diagnosis of rheumatoid arthritis. Arthritis Rheum 72:251–261

    Article  CAS  Google Scholar 

  124. Kongpachith S, Lingampalli N, Ju CH, Blum LK, Lu DR, Elliott SE et al (2019) Affinity maturation of the anti-citrullinated protein antibody paratope drives epitope spreading and polyreactivity in rheumatoid arthritis. Arthritis Rheum 71:507–517

    Article  CAS  Google Scholar 

  125. Lo KC, Sullivan E, Bannen RM, Jin H, Rowe M, Li H et al (2020) Comprehensive profiling of the rheumatoid arthritis antibody repertoire. Arthritis Rheum 72:242–250

    Article  CAS  Google Scholar 

  126. Schwenzer A, Quirke AM, Montgomery AB, Venables PJ, Sayles HR, Schlumberger W et al (2019) Time to include fine specificity anti-citrullinated protein antibodies in the routine diagnosis and management of rheumatoid arthritis? Arthritis Rheum 71:476–478

    Article  Google Scholar 

  127. Shelef MA (2019) New relationships for old autoantibodies in rheumatoid arthritis. Arthritis Rheum 71:1396–1399

    Article  Google Scholar 

  128. Zheng Z, Mergaert AM, Fahmy LM, Bawadekar M, Holmes CL, Ong IM et al (2020) Disordered antigens and epitope overlap between anti-citrullinated protein antibodies and rheumatoid factor in rheumatoid arthritis. Arthritis Rheum 72:262–272

    Article  CAS  Google Scholar 

  129. Ge C, Xu B, Liang B, Lonnblom E, Lundstrom SL, Zubarev RA et al (2019) Structural basis of cross-reactivity of anti-citrullinated protein antibodies. Arthritis Rheum 71:210–221

    Article  CAS  Google Scholar 

  130. Hafkenscheid L, de Moel E, Smolik I, Tanner S, Meng X, Jansen BC et al (2019) N-linked glycans in the variable domain of IgG anti-citrullinated protein antibodies predict the development of rheumatoid arthritis. Arthritis Rheum 71:1626–1633

    Article  CAS  Google Scholar 

  131. Holmdahl R (2019) The specificity of monoclonal anti-citrullinated protein antibodies: comment on the article by Steen et al. Arthritis Rheum 71:324–325

    Article  Google Scholar 

  132. Jain A, Shah H, Simonsick EM, Metter EJ, Mangold L, Humphreys E et al (2019) Angiotensin receptor autoantibodies as exposures that modify disease progression: cross sectional, longitudinal and in vitro studies of prostate cancer. J Transl Autoimmun 2

  133. Stathopoulos P, Chastre A, Waters P, Irani S, Fichtner ML, Benotti ES et al (2019) Autoantibodies against neurologic antigens in nonneurologic autoimmunity. J Immunol 202:2210–2219

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Fresquet M, Rhoden SJ, Jowitt TA, McKenzie EA, Roberts I, Lennon R et al (2020) Autoantigens PLA2R and THSD7A in membranous nephropathy share a common epitope motif in the N-terminal domain. J Autoimmun 106:102308

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Alhomaidan HT, Rasheed N, Almatrafi S, Al-Rashdi FH, Rasheed Z (2019) Bisphenol A modified DNA: a possible immunogenic stimulus for anti-DNA autoantibodies in systemic lupus erythematosus. Autoimmunity 52:272–280

    Article  CAS  PubMed  Google Scholar 

  136. Acosta-Herrera M, Kerick M, Gonzalez-Serna D, Wijmenga C, Franke A, Gregersen PK et al (2019) Genome-wide meta-analysis reveals shared new loci in systemic seropositive rheumatic diseases. Ann Rheum Dis 78:311–319

    Article  CAS  PubMed  Google Scholar 

  137. Akizuki S, Ishigaki K, Kochi Y, Law SM, Matsuo K, Ohmura K et al (2019) PLD4 is a genetic determinant to systemic lupus erythematosus and involved in murine autoimmune phenotypes. Ann Rheum Dis 78:509–518

    Article  CAS  PubMed  Google Scholar 

  138. Tkachenko O, Lapin S, Maslyansky A, Myachikova V, Guseva V, Belolipetskaia E et al (2019) Influence of HLA-DRB1 susceptibility alleles on the autoantibodies spectrum of systemic lupus erythematosus in European part of Russia. Autoimmun Rev 18:558–560

    Article  PubMed  Google Scholar 

  139. Shah AA, Laiho M, Rosen A, Casciola-Rosen L (2019) Protective effect against cancer of antibodies to the large subunits of both RNA polymerases I and III in scleroderma. Arthritis Rheum 71:1571–1579

    Article  CAS  Google Scholar 

  140. Pinal-Fernandez I, Amici DR, Parks CA, Derfoul A, Casal-Dominguez M, Pak K et al (2019) Myositis autoantigen expression correlates with muscle regeneration but not autoantibody specificity. Arthritis Rheum 71:1371–1376

    Article  CAS  Google Scholar 

  141. Mosanya CH, Isaacs JD (2019) Tolerising cellular therapies: what is their promise for autoimmune disease? Ann Rheum Dis 78:297–310

    Article  CAS  PubMed  Google Scholar 

  142. Scheinberg M, Azevedo V (2019) The future landscape of biosimilars in rheumatology: Where we are where we are going. Autoimmun Rev 18:203–208

    Article  PubMed  Google Scholar 

  143. Muhammad Yusoff F, Wong KK, Mohd Redzwan N (2020) Th1, Th2, and Th17 cytokines in systemic lupus erythematosus. Autoimmunity 53:8–20

    Article  CAS  PubMed  Google Scholar 

  144. Rahman S, Sagar D, Hanna RN, Lightfoot YL, Mistry P, Smith CK et al (2019) Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus. Ann Rheum Dis 78:957–966

    Article  CAS  PubMed  Google Scholar 

  145. Chan KK, Bass AR (2019) Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor. Ann Rheum Dis 78:e70

    Article  PubMed  Google Scholar 

  146. Delyon J, Brunet-Possenti F, Leonard-Louis S, Arangalage D, Baudet M, Baroudjian B et al (2019) Immune checkpoint inhibitor rechallenge in patients with immune-related myositis. Ann Rheum Dis 78:e129

    Article  PubMed  Google Scholar 

  147. Kostine M, Cappelli LC, Calabrese C, Calabrese LH, Bingham CO 3rd, Richez C et al (2019) Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists? Ann Rheum Dis 78:860–862

    Article  PubMed  Google Scholar 

  148. Mammen AL, Rajan A, Pak K, Lehky T, Casciola-Rosen L, Donahue RN et al (2019) Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. Ann Rheum Dis 78:150–152

    Article  CAS  PubMed  Google Scholar 

  149. Michot JM, Fusellier M, Champiat S, Velter C, Baldini C, Voisin AL et al (2019) Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1. Ann Rheum Dis 78:e67

    Article  PubMed  Google Scholar 

  150. Schaeverbeke T, Kostine M (2019) Response to: 'Checkpoint inhibitors and arthritis: seeking balance between victories and defeats' by Moura and Moura. Ann Rheum Dis 78:e92

    Article  PubMed  Google Scholar 

  151. McGonagle D, Bragazzi NL, Amital H, Watad A (2020) Mechanistic classification of immune checkpoint inhibitor toxicity as a pointer to minimal treatment strategies to further improve survival. Autoimmun Rev 19:102456

    Article  CAS  PubMed  Google Scholar 

  152. Kulik L, Laskowski J, Renner B, Woolaver R, Zhang L, Lyubchenko T et al (2019) Targeting the immune complex-bound complement C3d ligand as a novel therapy for lupus. J Immunol 203:3136–3147

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  153. Khan H, Sureda A, Belwal T, Cetinkaya S, Suntar I, Tejada S et al (2019) Polyphenols in the treatment of autoimmune diseases. Autoimmun Rev 18:647–657

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  154. Kim SY, Yu M, Morin EE, Kang J, Kaplan MJ, Schwendeman A (2020) High-density lipoprotein in lupus: disease biomarkers and potential therapeutic strategy. Arthritis Rheum 72:20–30

    Article  CAS  Google Scholar 

  155. Kitas GD, Nightingale P, Armitage J, Sattar N, Belch JJF, Symmons DPM (2019) A multicenter, randomized, placebo-controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 71:1437–1449

    Article  CAS  Google Scholar 

  156. Liao KP, Solomon DH (2019) Lipids and cardiovascular risk through the lens of rheumatoid arthritis. Arthritis Rheum 71:1393–1395

    Article  Google Scholar 

  157. Lopez-Mejias R, Carmona FD, Genre F, Remuzgo-Martinez S, Gonzalez-Juanatey C, Corrales A et al (2019) Identification of a 3'-untranslated genetic variant of RARB associated with carotid intima-media thickness in rheumatoid arthritis: a genome-wide association study. Arthritis Rheum 71:351–360

    Article  CAS  Google Scholar 

  158. Pellicciotta M, Rigoni R, Falcone EL, Holland SM, Villa A, Cassani B (2019) The microbiome and immunodeficiencies: lessons from rare diseases. J Autoimmun 98:132–148

    Article  CAS  PubMed  Google Scholar 

  159. Croci S, Bonacini M, Muratore F, Caruso A, Fontana A, Boiardi L et al (2019) The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis. J Autoimmun 98:113–121

    Article  CAS  PubMed  Google Scholar 

  160. Tsai HC, Nguyen K, Hashemi E, Engleman E, Hla T, Han MH (2019) Myeloid sphingosine-1-phosphate receptor 1 is important for CNS autoimmunity and neuroinflammation. J Autoimmun 105:102290

    Article  CAS  PubMed  Google Scholar 

  161. Alexopoulos H, Dalakas MC (2019) The immunobiology of autoimmune encephalitides. J Autoimmun 104:102339

    Article  CAS  PubMed  Google Scholar 

  162. Bronge M, Ruhrmann S, Carvalho-Queiroz C, Nilsson OB, Kaiser A, Holmgren E et al (2019) Myelin oligodendrocyte glycoprotein revisited-sensitive detection of MOG-specific T-cells in multiple sclerosis. J Autoimmun 102:38–49

    Article  CAS  PubMed  Google Scholar 

  163. Mattapallil MJ, Kielczewski JL, Zarate-Blades CR, St Leger AJ, Raychaudhuri K, Silver PB et al (2019) Interleukin 22 ameliorates neuropathology and protects from central nervous system autoimmunity. J Autoimmun 102:65–76

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  164. Brate AA, Boyden AW, Itani FR, Pewe LL, Harty JT, Karandikar NJ (2019) Therapeutic intervention in relapsing autoimmune demyelinating disease through induction of myelin-specific regulatory CD8 T cell responses. J Transl Autoimmun 2

  165. Shemer A, Willis R, Gonzalez EB, Romay-Penabad Z, Shovman O, Shoenfeld Y et al (2019) Oral administration of Domain-I of beta-2glycoprotein-I induces immunological tolerance in experimental murine antiphospholipid syndrome. J Autoimmun 99:98–103

    Article  CAS  PubMed  Google Scholar 

  166. Qureshi MS, Alsughayyir J, Chhabra M, Ali JM, Goddard MJ, Devine CA et al (2019) Germinal center humoral autoimmunity independently mediates progression of allograft vasculopathy. J Autoimmun 98:44–58

    Article  CAS  PubMed  Google Scholar 

  167. Alvarez-Sierra D, Marin-Sanchez A, Ruiz-Blazquez P, de Jesus GC, Iglesias-Felip C, Gonzalez O et al (2019) Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. J Autoimmun 103:102285

    Article  CAS  PubMed  Google Scholar 

  168. Das T, Bergen IM, Koudstaal T, van Hulst JAC, van Loo G, Boonstra A et al (2019) DNGR1-mediated deletion of A20/Tnfaip3 in dendritic cells alters T and B-cell homeostasis and promotes autoimmune liver pathology. J Autoimmun 102:167–178

    Article  CAS  PubMed  Google Scholar 

  169. Terziroli Beretta-Piccoli B, Di Bartolomeo C, Deleonardi G, Grondona AG, Silvestri T, Tesei C et al (2019) Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents. J Autoimmun 102:89–95

    Article  CAS  PubMed  Google Scholar 

  170. Huynh M, Eggenhuizen PJ, Olson GL, Rao NB, Self CR, Sun Y et al (2019) HLA-DR15-specific inhibition attenuates autoreactivity to the Goodpasture antigen. J Autoimmun 103:102276

    Article  CAS  PubMed  Google Scholar 

  171. Stremska ME, Dai C, Venkatadri R, Wang H, Sabapathy V, Kumar G et al (2019) IL233, an IL-2-IL-33 hybrid cytokine induces prolonged remission of mouse lupus nephritis by targeting Treg cells as a single therapeutic agent. J Autoimmun 102:133–141

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  172. Kolb H, Burkart V (2019) Chaperones may cause the focus of diabetes autoimmunity on distinct (pro)insulin peptides. J Autoimmun 105:102304

    Article  CAS  PubMed  Google Scholar 

  173. Tenspolde M, Zimmermann K, Weber LC, Hapke M, Lieber M, Dywicki J et al (2019) Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes. J Autoimmun 103:102289

    Article  CAS  PubMed  Google Scholar 

  174. Simakou T, Butcher JP, Reid S, Henriquez FL (2019) Alopecia areata: a multifactorial autoimmune condition. J Autoimmun 98:74–85

    Article  CAS  PubMed  Google Scholar 

  175. Erdei E, Shuey C, Pacheco B, Cajero M, Lewis J, Rubin RL (2019) Elevated autoimmunity in residents living near abandoned uranium mine sites on the Navajo Nation. J Autoimmun 99:15–23

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  176. Meier HCS, Parks CG, Liu HB, Sandler DP, Simonsick EM, Deane K et al (2019) Cellular aging over 13 years associated with incident antinuclear antibody positivity in the Baltimore Longitudinal Study of Aging. J Autoimmun 105:102295

    Article  PubMed  PubMed Central  Google Scholar 

  177. Essouma M, Nkeck JR, Endomba FT, Bigna JJ, Singwe-Ngandeu M, Hachulla E (2020) Systemic lupus erythematosus in Native sub-Saharan Africans: a systematic review and meta-analysis. J Autoimmun 106:102348

    Article  CAS  PubMed  Google Scholar 

  178. Tanner S, Dufault B, Smolik I, Meng X, Anaparti V, Hitchon C et al (2019) A prospective study of the development of inflammatory arthritis in the family members of indigenous North American people with rheumatoid arthritis. Arthritis Rheum 71:1494–1503

    Article  CAS  Google Scholar 

  179. Desai RJ, Jin Y, Franklin PD, Lee YC, Bateman BT, Lii J et al (2019) Association of geography and access to health care providers with long-term prescription opioid use in Medicare patients with severe osteoarthritis: a cohort study. Arthritis Rheum 71:712–721

    Article  CAS  Google Scholar 

  180. Kronzer VL, Crowson CS, Sparks JA, Vassallo R, Davis JM 3rd. (2019) Investigating asthma, allergic disease, passive smoke exposure, and risk of rheumatoid arthritis. Arthritis Rheum 71:1217–1224

    Article  Google Scholar 

  181. Liu X, Tedeschi SK, Lu B, Zaccardelli A, Speyer CB, Costenbader KH et al (2019) Long-term pysical activity and subsequent risk for rheumatoid arthritis among women: a prospective cohort study. Arthritis Rheum 71:1460–1471

    Article  Google Scholar 

  182. Lee YC, Kremer J, Guan H, Greenberg J, Solomon DH (2019) Chronic opioid use in rheumatoid arthritis: prevalence and predictors. Arthritis Rheum 71:670–677

    Article  CAS  Google Scholar 

  183. Chang C, Gershwin ME (2019) The myth of mycotoxins and mold injury. Clin Rev Allergy Immunol 57:449–455

    Article  CAS  PubMed  Google Scholar 

  184. Yamamoto E, Jorgensen TN (2019) Immunological effects of vitamin D and their relations to autoimmunity. J Autoimmun 100:7–16

    Article  CAS  PubMed  Google Scholar 

  185. Huang C, Yi X, Long H, Zhang G, Wu H, Zhao M et al (2020) Disordered cutaneous microbiota in systemic lupus erythematosus. J Autoimmun 108:102391

    Article  PubMed  Google Scholar 

  186. van der Meulen TA, Harmsen HJM, Vila AV, Kurilshikov A, Liefers SC, Zhernakova A et al (2019) Shared gut, but distinct oral microbiota composition in primary Sjogren's syndrome and systemic lupus erythematosus. J Autoimmun 97:77–87

    Article  PubMed  Google Scholar 

  187. Amaya-Uribe L, Rojas M, Azizi G, Anaya JM, Gershwin ME (2019) Primary immunodeficiency and autoimmunity: a comprehensive review. J Autoimmun 99:52–72

    Article  CAS  PubMed  Google Scholar 

  188. Jamee M, Moniri S, Zaki-Dizaji M, Olbrich P, Yazdani R, Jadidi-Niaragh F et al (2019) Clinical, immunological, and genetic features in patients with activated PI3K delta syndrome (APDS): a systematic review. Clin Rev Allergy Immunol

  189. Gokhale AS, Gangaplara A, Lopez-Occasio M, Thornton AM, Shevach EM (2019) Selective deletion of Eos (Ikzf4) in T-regulatory cells leads to loss of suppressive function and development of systemic autoimmunity. J Autoimmun 105:102300

    Article  CAS  PubMed  Google Scholar 

  190. Lourou N, Gavriilidis M, Kontoyiannis DL (2019) Lessons from studying the AU-rich elements in chronic inflammation and autoimmunity. J Autoimmun 104:102334

    Article  CAS  PubMed  Google Scholar 

  191. Lundtoft C, Seyfarth J, Oberstrass S, Rosenbauer J, Baechle C, Roden M et al (2019) Autoimmunity risk- and protection-associated IL7RA genetic variants differentially affect soluble and membrane IL-7R alpha expression. J Autoimmun 97:40–47

    Article  CAS  PubMed  Google Scholar 

  192. Morianos I, Papadopoulou G, Semitekolou M, Xanthou G (2019) Activin-A in the regulation of immunity in health and disease. J Autoimmun 104:102314

    Article  CAS  PubMed  Google Scholar 

  193. Pacheco Y, Acosta-Ampudia Y, Monsalve DM, Chang C, Gershwin ME, Anaya JM (2019) Bystander activation and autoimmunity. J Autoimmun 103:102301

    Article  CAS  PubMed  Google Scholar 

  194. Saferding V, Bluml S (2020) Innate immunity as the trigger of systemic autoimmune diseases. J Autoimmun 110:102382

    Article  CAS  PubMed  Google Scholar 

  195. Vlachiotis S, Andreakos E (2019) Lambda interferons in immunity and autoimmunity. J Autoimmun 104:102319

    Article  CAS  PubMed  Google Scholar 

  196. Yao L, Zhou L, Xuan Y, Zhang P, Wang X, Wang T et al (2019) The proteasome activator REG gamma counteracts immunoproteasome expression and autoimmunity. J Autoimmun 103:102282

    Article  PubMed  CAS  Google Scholar 

  197. Chen B, Vousden KA, Naiman B, Turman S, Sun H, Wang S et al (2019) Humanised effector-null Fc gamma RIIA antibody inhibits immune complex-mediated proinflammatory responses. Ann Rheum Dis 78:228–237

    Article  CAS  PubMed  Google Scholar 

  198. Stohl W, Yu N, Chalmers S, Putterman C, Jacob CO (2020) Development of murine systemic lupus erythematosus in the absence of BAFF. Arthritis Rheum 72:292–302

    Article  CAS  Google Scholar 

  199. Xiao N, Wei J, Xu S, Du H, Huang M, Zhang S et al (2019) cGAS activation causes lupus-like autoimmune disorders in a TREX1 mutant mouse model. J Autoimmun 100:84–94

    Article  CAS  PubMed  Google Scholar 

  200. Wade SM, Trenkmann M, McGarry T, Canavan M, Marzaioli V, Wade SC et al (2019) Altered expression of microRNA-23a in psoriatic arthritis modulates synovial fibroblast pro-inflammatory mechanisms via phosphodiesterase 4B. J Autoimmun 96:86–93

    Article  CAS  PubMed  Google Scholar 

  201. Mustelin T, Bottini N, Stanford SM (2019) The contribution of PTPN22 to rheumatic disease. Arthritis Rheum 71:486–495

    Article  CAS  Google Scholar 

  202. Tison A, Quere G, Misery L, Funck-Brentano E, Danlos FX, Routier E et al (2019) Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheum 71:2100–2111

    Article  CAS  Google Scholar 

  203. Alissafi T, Hatzioannou A, Legaki AI, Varveri A, Verginis P (2019) Balancing cancer immunotherapy and immune-related adverse events: the emerging role of regulatory T cells. J Autoimmun 104:102310

    Article  CAS  PubMed  Google Scholar 

  204. Thiel J, Alter C, Luppus S, Eckstein A, Tan S, Fuhrer D et al (2019) MicroRNA-183 and microRNA-96 are associated with autoimmune responses by regulating T cell activation. J Autoimmun 96:94–103

    Article  CAS  PubMed  Google Scholar 

  205. Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, Seve P (2019) JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev 18:102390

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center – IRCCS, via Manzoni 56, Rozzano, 20089, Milan, Italy

    Carlo Selmi

  2. Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, 20090, Pieve Emanuele-Milan, Italy

    Carlo Selmi

Authors
  1. Carlo Selmi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlo Selmi.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Selmi, C. Autoimmunity in 2019. Clinic Rev Allerg Immunol 59, 275–286 (2020). https://doi.org/10.1007/s12016-020-08808-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-020-08808-3

Keywords

Search

Navigation